Page 6 - Global External News Today

Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva's partner AbbVie for cedirogant Phase IIb

Investegate announcements from INVENTIVA, Inventiva reports its 2022 first-half financial results and provides a corporate update

Investegate announcements from INVENTIVA, Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China

Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater ChinaLanifibranor is an orally-available small molecule

Daix (France), Long Island City (New York, United States), September 7, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development

Investegate announcements from INVENTIVA, Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

Conference Call August 12, 2022 at 11:00 AM (EDT) (All figures reported in USD) Revised production, EBITDA and Cost guidance due to lower than expected performance at Bolivar and Cusi, offset

/PRNewswire/ -- On Monday, August 8, Orbis International, with generous support from Alcon, the global leader in eye care, will kick off its first in-person...

/PRNewswire/ -- On Monday, August 8, Orbis International, with generous support from Alcon, the global leader in eye care, will kick off its first in-person...

The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with... | July 7, 2022